Compare HFFG & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | VANI |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | United States | United States |
| Employees | 1074 | N/A |
| Industry | Food Distributors | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.0M | 95.8M |
| IPO Year | 2016 | 2014 |
| Metric | HFFG | VANI |
|---|---|---|
| Price | $2.08 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 207.5K | ★ 210.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,201,667,000.00 | $4,000,000.00 |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.63 | N/A |
| 52 Week Low | $1.38 | $0.91 |
| 52 Week High | $4.93 | $1.92 |
| Indicator | HFFG | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 62.60 | 38.84 |
| Support Level | $1.38 | N/A |
| Resistance Level | $2.34 | $1.23 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 81.82 | 7.89 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.